Your browser is no longer supported. Please, upgrade your browser.
Settings
MGEN Miragen Therapeutics, Inc. daily Stock Chart
MGEN [NASD]
Miragen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.97 Insider Own0.50% Shs Outstand56.61M Perf Week-2.34%
Market Cap41.55M Forward P/E- EPS next Y-0.51 Insider Trans0.00% Shs Float53.12M Perf Month-16.00%
Income-35.80M PEG- EPS next Q-0.13 Inst Own19.10% Short Float3.30% Perf Quarter-23.51%
Sales2.60M P/S15.98 EPS this Y-20.90% Inst Trans-5.56% Short Ratio0.83 Perf Half Y73.84%
Book/sh0.40 P/B2.03 EPS next Y7.30% ROA-101.20% Target Price- Perf Year5.01%
Cash/sh0.60 P/C1.36 EPS next 5Y- ROE-164.50% 52W Range0.31 - 2.27 Perf YTD68.95%
Dividend- P/FCF- EPS past 5Y52.00% ROI-174.20% 52W High-64.28% Beta2.10
Dividend %- Quick Ratio4.80 Sales past 5Y0.60% Gross Margin- 52W Low160.71% ATR0.07
Employees45 Current Ratio4.80 Sales Q/Q-92.00% Oper. Margin- RSI (14)40.63 Volatility9.26% 8.33%
OptionableNo Debt/Eq0.42 EPS Q/Q57.80% Profit Margin- Rel Volume0.20 Prev Close0.81
ShortableYes LT Debt/Eq0.25 EarningsAug 05 AMC Payout- Avg Volume2.11M Price0.81
Recom1.50 SMA20-7.01% SMA50-19.66% SMA200-1.35% Volume429,453 Change0.33%
Dec-12-19Downgrade Robert W. Baird Outperform → Neutral $5 → $1
Jan-04-19Initiated Robert W. Baird Outperform
Dec-31-18Resumed B. Riley FBR Buy $18.50
Mar-29-18Initiated Jefferies Buy $14
Mar-09-18Initiated Evercore ISI Outperform $19
Jan-05-18Initiated B. Riley FBR, Inc. Buy $15.50
Sep-14-20 05:00PM  
Aug-24-20 02:17PM  
Aug-20-20 04:05PM  
Aug-05-20 07:05PM  
04:05PM  
Aug-04-20 08:00AM  
Jul-29-20 12:33PM  
Jul-28-20 08:00AM  
Jul-23-20 04:32PM  
Jul-22-20 08:00AM  
Jul-02-20 04:15PM  
Jun-23-20 07:57AM  
Jun-22-20 05:08PM  
Jun-19-20 07:41AM  
Jun-18-20 04:05PM  
10:15AM  
Jun-16-20 04:01PM  
Jun-04-20 09:34PM  
May-27-20 09:49AM  
May-26-20 08:00AM  
May-12-20 08:49AM  
May-07-20 04:05PM  
Apr-30-20 12:34PM  
Apr-23-20 08:00AM  
Mar-13-20 10:01AM  
Mar-11-20 05:45PM  
04:05PM  
02:30PM  
Mar-04-20 12:30PM  
Feb-20-20 08:00AM  
Feb-14-20 11:30AM  
Feb-07-20 09:00AM  
Feb-06-20 04:03PM  
Jan-31-20 10:41AM  
Jan-30-20 07:00AM  
Jan-23-20 08:00AM  
Dec-13-19 08:10AM  
Dec-12-19 07:38AM  
Dec-11-19 04:05PM  
Nov-26-19 08:00AM  
Nov-12-19 01:51PM  
Nov-07-19 06:45PM  
04:01PM  
Oct-31-19 10:33AM  
Oct-28-19 09:00AM  
Oct-22-19 08:00AM  
Oct-16-19 02:45AM  
Aug-15-19 08:00AM  
Aug-12-19 08:00AM  
Aug-07-19 08:45PM  
04:05PM  
Jul-31-19 10:36AM  
Jul-24-19 08:00AM  
Jun-21-19 01:45PM  
May-28-19 04:30PM  
May-21-19 07:00AM  
May-08-19 06:35PM  
04:01PM  
May-01-19 10:32AM  
Apr-29-19 07:00AM  
Apr-28-19 10:42AM  
Apr-26-19 07:00AM  
Apr-25-19 08:00AM  
Mar-14-19 11:48PM  
Mar-13-19 05:40PM  
04:05PM  
Mar-06-19 08:00AM  
Feb-20-19 08:00AM  
Jan-24-19 09:05AM  
Jan-10-19 07:00AM  
Dec-20-18 07:00AM  
Dec-18-18 10:11AM  
Dec-05-18 04:05PM  
Dec-02-18 05:00PM  
Nov-07-18 06:40PM  
04:01PM  
Nov-01-18 09:00AM  
Oct-29-18 07:00AM  
Oct-24-18 07:00AM  
Oct-01-18 07:00AM  
Aug-07-18 04:05PM  
02:30PM  
Aug-06-18 07:00AM  
Jul-31-18 07:00AM  
Jul-25-18 07:00AM  
Jul-10-18 07:00AM  
Jul-03-18 12:38PM  
Jun-04-18 07:30AM  
May-31-18 07:00AM  
May-16-18 05:00PM  
May-09-18 04:05PM  
May-08-18 09:23PM  
04:05PM  
May-02-18 04:05PM  
07:00AM  
May-01-18 07:00AM  
Apr-30-18 04:05PM  
Apr-27-18 07:00AM  
Apr-19-18 07:00AM  
Mar-27-18 07:00AM  
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leverone Jason A.CFO, Treasurer & SecretaryMar 13Option Exercise0.5711,2496,41248,829Mar 17 04:22 PM